Bob Mauch
| Bob Mauch | |
| Born | Robert P. Mauch |
|---|---|
| Nationality | American |
| Occupation | Corporate executive, pharmacist |
| Title | President and Chief Executive Officer, Cencora, Inc. |
| Known for | President and CEO of Cencora, Inc. (formerly AmerisourceBergen) |
| Education | PharmD, PhD |
Robert P. Mauch, PharmD, PhD, is an American corporate executive and pharmacist who serves as the President and Chief Executive Officer of Cencora, Inc. (NYSE: COR), one of the largest pharmaceutical distribution companies in the United States. He assumed the role of President and CEO in October 2024, succeeding Steven H. Collis, who transitioned to the position of executive chairman of the company's board of directors.[1] Before becoming CEO, Mauch served as the company's Chief Operating Officer, overseeing the operational strategy and infrastructure of a firm that distributes pharmaceutical products to healthcare providers, pharmacies, and manufacturers across the globe. His leadership has been characterized by significant investment in the company's U.S. distribution network and a focus on innovations aimed at accelerating the delivery of treatments to patients.[2] Mauch holds both a Doctor of Pharmacy (PharmD) and a Doctor of Philosophy (PhD), reflecting a career grounded in pharmaceutical science and healthcare operations.[3]
Education
Robert P. Mauch holds two doctoral-level degrees: a Doctor of Pharmacy (PharmD) and a Doctor of Philosophy (PhD).[3] His academic background in pharmaceutical sciences provided a foundation for his career in the healthcare and pharmaceutical distribution industry. The dual doctoral credentials distinguish him among pharmaceutical industry executives and reflect a trajectory that combined clinical pharmacy training with advanced research.[4]
Career
Early Career and Rise at AmerisourceBergen
Before ascending to the top leadership role at Cencora, Mauch built an extensive career within the company, which was formerly known as AmerisourceBergen prior to its rebranding in 2023. He progressed through a series of leadership positions that gave him broad operational experience across the firm's pharmaceutical distribution and services businesses. By the time of his appointment as Chief Operating Officer, Mauch had developed deep expertise in the logistics, regulatory, and commercial dimensions of large-scale pharmaceutical distribution.[5]
Chief Operating Officer
As Chief Operating Officer of Cencora, Mauch was responsible for overseeing the day-to-day operations of the company's vast distribution network. The company, headquartered in Conshohocken, Pennsylvania, ranks among the largest pharmaceutical distributors in the United States, playing a central role in the supply chain that connects drug manufacturers with pharmacies, hospitals, and other healthcare providers.[5] In this capacity, Mauch managed the operational infrastructure that facilitated the movement of pharmaceutical products worth billions of dollars annually. His tenure as COO positioned him as the leading internal candidate to succeed Steven Collis, who had served as CEO since 2011.[1]
Appointment as President and CEO
On March 12, 2024, Cencora announced that Mauch would succeed Steven H. Collis as President and Chief Executive Officer, effective October 2024. Collis, who had led the company through its rebranding from AmerisourceBergen to Cencora and had overseen a period of significant growth, announced his plans to transition to the role of executive chairman of the board of directors.[1] The succession plan was described by the company as a planned leadership transition designed to ensure continuity in strategic direction.
The Philadelphia Inquirer reported that the selection of Mauch, who was already serving as COO, reflected the board's confidence in his operational leadership and his understanding of the pharmaceutical distribution landscape.[5] The announcement also noted that Mauch would simultaneously be appointed as a member of the Cencora board of directors upon assuming the CEO role.[4]
Mauch formally assumed the position of President and CEO in October 2024.[3] Upon taking the helm, he stated that his focus would be on building on the company's existing strengths while addressing the evolving complexities of pharmaceutical distribution.[6]
Leadership of Cencora
During his first year as CEO, Mauch oversaw several strategic initiatives aimed at strengthening Cencora's position in the pharmaceutical distribution industry. In an October 2025 interview with Pharmaceutical Executive, Mauch discussed lessons learned during his first year leading the company and the challenges posed by an increasingly complex future for pharmaceutical distribution. He addressed topics including the need to adapt distribution infrastructure to accommodate new types of therapies, including specialty pharmaceuticals and cell and gene therapies, which require different handling and logistics compared to traditional medications.[6]
$1 Billion Investment Initiative
One of the most significant strategic moves under Mauch's leadership was announced in November 2025, when Cencora disclosed plans to invest more than $1 billion through 2030 to expand its U.S. drug distribution network. The investment, reported by Reuters, was described as part of the company's effort to modernize and scale its distribution capabilities in response to growing demand for pharmaceutical products and the increasing complexity of the supply chain.[2]
The announcement coincided with the release of Cencora's fiscal 2025 fourth quarter and fiscal year-end results for the period ended September 30, 2025. The company reported that revenue in the fiscal year 2025 fourth quarter increased 5.9 percent compared to the prior-year period, and the company issued an upbeat forecast for fiscal year 2026.[7] The positive financial results and the ambitious investment plan signaled confidence in the company's growth trajectory under Mauch's leadership.
Innovations in Pharmaceutical Distribution
In a December 2025 feature published by Modern Healthcare, Mauch discussed the transformation of pharmaceutical distribution from a primarily warehouse-based logistics operation to a more integrated component of the broader healthcare ecosystem. The interview, titled "Warehouse to wellness," explored Mauch's perspective on how Cencora was working to deliver vital medicines to patients more efficiently and on innovations designed to reduce the time required to bring treatments from manufacturers to the point of care.[8]
Mauch emphasized the role of technology and data in improving distribution operations, as well as the importance of the distributor's position in ensuring supply chain resilience—a topic that gained heightened prominence during and after the COVID-19 pandemic, which exposed vulnerabilities in pharmaceutical and medical supply chains globally.[8]
Business Roundtable Membership
Following his appointment as CEO of Cencora, Mauch was included as a member of the Business Roundtable, an association of chief executive officers of major U.S. companies. His membership in the organization, which advocates on economic and policy issues, reflects Cencora's standing as one of the largest companies in the American healthcare sector.[3]
Cencora Under Mauch's Leadership
Cencora, Inc. (NYSE: COR), the company Mauch leads, is one of the largest pharmaceutical distribution and solutions companies in the world. Formerly known as AmerisourceBergen, the company rebranded as Cencora in 2023. It is headquartered in Conshohocken, Pennsylvania, a suburb of Philadelphia.[5]
The company's core business involves the distribution of branded and generic pharmaceutical products, over-the-counter healthcare products, and home healthcare supplies to a broad range of healthcare providers. Cencora's customers include retail pharmacies, hospital systems, mail-order pharmacies, long-term care facilities, and physicians' offices across the United States and internationally.[2]
Under Mauch's leadership, the company has continued to pursue growth both organically and through strategic investments. The announcement of over $1 billion in planned U.S. distribution network investments through 2030 represented one of the largest infrastructure commitments in the pharmaceutical distribution sector.[2] The company's fiscal 2025 results, which showed year-over-year revenue growth and a positive outlook for fiscal 2026, indicated operational stability during the CEO transition period.[7]
The pharmaceutical distribution industry in which Cencora operates is characterized by thin profit margins, high volumes, and intense regulatory scrutiny. Companies in this sector have also faced legal and public scrutiny related to the opioid crisis in the United States. Mauch's leadership has focused on navigating these challenges while positioning the company for long-term growth through investment in technology, infrastructure, and service capabilities.[6]
Recognition
Mauch's selection as CEO of one of the largest companies in the U.S. pharmaceutical supply chain was covered by major business and healthcare media outlets, including The Philadelphia Inquirer, Drug Store News, Pharmaceutical Executive, Modern Healthcare, and Reuters.[5][1][6][8][2]
His membership in the Business Roundtable, an organization comprising the CEOs of America's leading companies, serves as an indicator of his standing within the broader U.S. business community.[3] The Pharmaceutical Executive profile published in October 2025, marking approximately one year since he assumed the CEO role, highlighted his strategic vision for Cencora's future in an evolving pharmaceutical landscape.[6]
The December 2025 Modern Healthcare feature further recognized Mauch as a significant voice in the ongoing discussion about the modernization of pharmaceutical distribution and its implications for patient care and healthcare delivery.[8]
References
- ↑ 1.0 1.1 1.2 1.3 "Cencora's CEO Steve Collis to retire, Robert Mauch to take reins as president/CEO".Drug Store News.2024-03-14.https://drugstorenews.com/cencoras-ceo-steve-collis-retire-robert-mauch-take-reins-presidentceo.Retrieved 2026-02-23.
- ↑ 2.0 2.1 2.2 2.3 2.4 "Cencora to invest $1 billion on US drug distribution, posts upbeat 2026 forecast".Reuters.2025-11-05.https://www.reuters.com/business/healthcare-pharmaceuticals/cencora-invest-1-billion-us-drug-distribution-posts-upbeat-2026-forecast-2025-11-05/.Retrieved 2026-02-23.
- ↑ 3.0 3.1 3.2 3.3 3.4 "Robert P. Mauch, PharmD, PhD".Business Roundtable.2024-10-28.https://www.businessroundtable.org/about-us/members/robert-p.-mauch,-pharmd,-phd.Retrieved 2026-02-23.
- ↑ 4.0 4.1 "Robert Mauch Appointed CEO of Cencora".citybiz.2024-03-12.https://www.citybiz.co/article/530786/robert-mauch-appointed-ceo-of-cencora/.Retrieved 2026-02-23.
- ↑ 5.0 5.1 5.2 5.3 5.4 "Cencora, a massive pharma distributor based in Conshohocken, announces CEO succession plan".The Philadelphia Inquirer.2024-03-12.https://www.inquirer.com/health/cencora-ceo-bob-mauch-replaces-steve-collis-20240312.html.Retrieved 2026-02-23.
- ↑ 6.0 6.1 6.2 6.3 6.4 "Bob Mauch: Strengthening the Chain".Pharmaceutical Executive.2025-10-21.https://www.pharmexec.com/view/bob-mauch-strengthening-the-chain.Retrieved 2026-02-23.
- ↑ 7.0 7.1 "Cencora Reports Fiscal 2025 Fourth Quarter and Fiscal Year End Results".Business Wire.2025-11-05.https://www.businesswire.com/news/home/20251105392361/en/Cencora-Reports-Fiscal-2025-Fourth-Quarter-and-Fiscal-Year-End-Results.Retrieved 2026-02-23.
- ↑ 8.0 8.1 8.2 8.3 "Warehouse to wellness: Bob Mauch on modern pharmaceutical distribution".Modern Healthcare.2025-12-08.http://www.modernhealthcare.com/providers/mh-warehouse-to-wellness-mauch-modern-pharmaceutical-distribution/.Retrieved 2026-02-23.